Spotlight Stories

1. Annovis Bio: Against The Grain In Alzheimer's Disease 10/1/2024

   From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape. 

2. Cash Needed For Phase 3 Celiac Drug Development 6/28/2024

   Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line.

3. Partnering To Address 'Huge' Opportunities In Women's Health 6/14/2024

   Nonprofit research foundations can offer scientific expertise and support for biopharmaceutical drug development and clinical programs, helping companies improve new and existing drugs for women.

4. Reviva Pharma's Novel Funding Approach In Schizophrenia 4/25/2024

   Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.

5. A View From The Co-Chair Of Israel's Biopharma Industry Trade Organization 3/28/2024

   Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.

6. NORD Expands Advocacy And Support For Rare Disease Patients, And Industry 2/29/2024

   NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.

7. No Playbook For Leqembi: Eisai's Long Game In Alzheimer's Disease 2/16/2024

   Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.

8. Dynavax's Evolving Business Model 2/9/2024

   Dynavax found a new revenue stream during COVID, and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs, and his own journey to CEO role.

9. Empress Builds Base for Small-Molecule Innovation 2/1/2024

   Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.

10. That Price Is WAC: Boehringer's Push For Access To Humira Biosimilars 1/29/2024

    Boehringer Ingelheim's biosimilar commercial brand leader explains the company's two-tier pricing approach with Cyltezo, an interchangeable Humira biosimilar, and what new FDA guidance on interchangeability means for patients and physicians.